UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 26, 2025

KNOW LABS, INC.

(Exact name of registrant as specified in its charter)

Nevada	
(State or other jurisdiction	
of incorporation)	

001-37479 (Commission 90-0273142

File Number)

(IRS Employer Identification No.)

619 Western Avenue, Suite 610, Seattle, Washington

(Address of principal executive offices)

98104 (Zip Code)

(206) 903-1351

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001	KNWN	OTCQB Venture Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging Growth Company \Box

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

Item 7.01 Regulation FD Disclosure.

On February 27, 2025, Know Labs, Inc., a Nevada corporation (the "Company") issued a press release announcing the commencement of trading on the OTCQB Venture Market described under Item 8.01 below.

The information included in this Item 7.01 of this Current Report on Form 8-K, including the attached Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 8.01 Other Events

On February 26, 2025, the Company was approved to be upgraded for quotation to the OTC Market's Group Inc.'s OTCQB Venture Market (the "OTCQB"), under the ticker symbol "KNWN", effective as of the open of trading February 26, 2025. As previously disclosed, the Company's OTC trading symbol is "KNWND", with the "D" temporarily allotted for twenty (20) days, effective on February 19, 2025 in connection with the reverse stock split which was announced by FINRA on February 18, 2025.

Item 9.01 Financial Statements and Exhibits.

(d)	Exhibits
<u>99.1</u>	Press Release dated February 27, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 27, 2025

KNOW LABS, INC.

/s/ Ronald P. Erickson Name: Ronald P. Erickson Title: Chairman of the Board

Know Labs Announces Approval to Begin Trading on the OTCQB Market

Seattle, WA – February 27, 2025 – Know Labs, Inc. (OTC: KNWN) a leading innovator in Radio Frequency Dielectric Spectroscopy (RFDS) sensor technology announced today that the Company's common shares have been approved to quote on the OTC Markets Group Inc.'s OTCQB Venture Market (the "OTCQB") under the ticker symbol "KNWN" effective as of the open of trading on February 26, 2025. As previously disclosed, the Company's trading symbol has been affixed with a "D", temporarily allotted for twenty (20) days, effective on February 19, 2025 following announcement of the reverse stock split by FINRA on February 18, 2025.

The OTCQB is recognized as an "established public market" by the U.S. Securities and Exchange Commission and is a leading market for U.S. and international companies in the entrepreneurial and development stage. To be eligible, companies must be current in their financial reporting, pass a minimum bid price test, and undergo an annual company verification and detailed certification process. The OTCQB quality standards are expected to provide increased transparency and more detail on market depth including greater disclosure of market makers as well as improved liquidity. As a verified market with efficient access to U.S. investors, OTCQB helps companies build shareholder value with the goal of enhancing liquidity and achieving a fair valuation.

OTC Markets Group Inc. provides price and liquidity information for almost 10,000 over-the-counter securities. The group's headquarters are in New York City. OTC securities are organized into three markets to inform investors of opportunities and risks: OTCQX, OTCQB, and OTCID.

About Know Labs, Inc.

Know Labs, Inc.'s platform technology uses radio frequency dielectric spectroscopy (RFDS) to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology is designed to be able to integrate into a variety of wearable, mobile or bench-top form factors. The Company believes that this patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. Among the Company's first expected applications of the technology will be in a product marketed as a non-invasive glucose monitor. The device is designed to provide the user with accessible and affordable real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration (FDA) clearance prior to its introduction to the market. Other products, developed through Know Labs Technology License ("KTL") program, may not require such prior FDA approval.

Safe Harbor Statement

This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words "may," "will," "could," "should," "und," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," "likely," "forecast," "probable," "potential," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.'s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company's filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2024, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at <u>www.knowlabs.co</u>. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligatio

Know Labs, Inc. Contact:

Investor Relations T: 206-903-1351 ask@knowlabs.co